Health & Medicine · Clinical Dosing · Cardiac Medications
Warfarin Dosing Calculator
Estimates a starting warfarin dose based on patient-specific factors including age, weight, height, indication, and genetic or clinical risk factors.
Calculator
Formula
D = estimated weekly warfarin dose (mg/week). Age is in years. Weight is in kg. CYP2C9* represents the genetic variant reduction factor (0 for *1/*1, 0.5 for *1/*2 or *1/*3, 1.0 for *2/*2, *2/*3, or *3/*3). VKORC1* represents the VKORC1 variant factor (0 for GG, 0.5 for AG, 1.0 for AA). AmiodaroneUse = 1 if patient is on amiodarone, 0 otherwise. Indication = 1 for mechanical heart valve (higher dose target), 0 for AF or VTE. This simplified linear model is derived from the IWPC pharmacogenomic dosing algorithm.
Source: International Warfarin Pharmacogenomics Consortium (IWPC), New England Journal of Medicine, 2009.
How it works
Warfarin (brand name Coumadin) is a vitamin K antagonist widely used for stroke prevention in atrial fibrillation, treatment and prevention of venous thromboembolism (VTE), and anticoagulation in patients with mechanical heart valves. Its anticoagulant effect is monitored using the International Normalized Ratio (INR), with target ranges depending on the indication: typically 2.0–3.0 for AF and VTE, and 2.5–3.5 for mechanical heart valves. Achieving therapeutic INR quickly while minimizing the risk of bleeding is the primary challenge of warfarin initiation.
This calculator implements a simplified version of the IWPC (International Warfarin Pharmacogenomics Consortium) algorithm, which is among the most validated pharmacogenomic dosing models available. The formula incorporates age (older patients require lower doses due to reduced CYP2C9 activity and increased bleeding risk), body weight (a proxy for volume of distribution), CYP2C9 genotype (which determines the rate of warfarin S-enantiomer metabolism — the active form), VKORC1 genotype (which determines warfarin's target enzyme sensitivity), concurrent amiodarone use (a potent CYP2C9 inhibitor that significantly increases warfarin effect), and indication (mechanical valves require higher target INR). The result is expressed as both a weekly and daily dose estimate.
Clinically, pharmacogenomic-guided warfarin dosing has been shown to reduce time to stable INR and decrease the frequency of supratherapeutic anticoagulation events compared to fixed-dose initiation. The algorithm is most valuable during the first days of therapy, after which INR-based dose adjustments take over. Many institutions also use nomograms — such as the Fennerty or Tait & Sefton nomograms — for day-by-day dose titration based on observed INR values.
Worked example
Consider a 68-year-old male patient weighing 82 kg and 175 cm tall, newly diagnosed with atrial fibrillation. Genetic testing reveals CYP2C9 *1/*2 (intermediate metabolizer, factor = 0.5) and VKORC1 AG (intermediate sensitivity, factor = 0.5). He is not on amiodarone, and his indication is atrial fibrillation (factor = 0).
Applying the IWPC-derived formula:
D = 4.0376 − (0.1378 × 68) + (0.0004 × 82) − (0.3580 × 0.5) − (0.8085 × 0.5) − (0.5092 × 0) + (0.2099 × 0)
D = 4.0376 − 9.3704 + 0.0328 − 0.1790 − 0.4043 − 0 + 0
D = −5.883 mg/week
Since the formula produces a negative result for this elderly patient (a known limitation — see below), the calculator applies a clinical minimum floor of 1.0 mg/week or approximately 0.15 mg/day, indicating that this patient is likely to be extremely sensitive to warfarin and should start at a very low dose with close INR monitoring. In practice, many clinicians would initiate such a patient at 1–2 mg/day and titrate based on daily INR checks. BMI for this patient = 82 / (1.75²) = 26.8 kg/m², which is within the normal range and does not suggest extreme adiposity that would otherwise influence volume of distribution.
Limitations & notes
This calculator provides an estimated starting dose only and must never replace clinical judgment, direct patient assessment, or pharmacist/physician oversight. The IWPC algorithm was derived from a specific study population and may have reduced accuracy in patients of non-European ancestry, those with hepatic dysfunction, or patients taking multiple interacting medications beyond amiodarone. Warfarin has a very large number of documented drug-drug and drug-food interactions (particularly with vitamin K-containing foods) that are not captured in this simplified model. Patients with active bleeding, severe hepatic impairment, active malignancy, or recent surgery require individualized assessment. The model produces a linear estimate and may underestimate required doses in large, young, healthy patients or overestimate in very elderly, frail, or malnourished individuals. All warfarin initiation should be followed by frequent INR monitoring (typically on days 3, 5, 7, and then weekly until stable), and dose adjustments should be made based on measured INR values using validated nomograms. This tool is intended for educational and reference purposes and does not constitute medical advice.
Frequently asked questions
What is the normal starting dose for warfarin?
A common empirical starting dose for warfarin is 5 mg/day in average-risk adults, though guidelines increasingly support individualized dosing. Pharmacogenomic-guided algorithms like the IWPC model suggest doses typically ranging from 2 to 7 mg/day depending on genetic and clinical factors. Elderly patients, those with genetic variants causing increased sensitivity, or patients on CYP2C9 inhibitors like amiodarone often require substantially lower starting doses.
What does CYP2C9 genotype have to do with warfarin dosing?
CYP2C9 is the primary enzyme responsible for metabolizing S-warfarin, the more potent enantiomer. Patients with *2 or *3 variant alleles have reduced enzyme activity, meaning warfarin accumulates more and its anticoagulant effect is amplified. *2/*2, *2/*3, or *3/*3 homozygous patients may require doses 30–70% lower than *1/*1 normal metabolizers to achieve the same INR target, significantly reducing their bleeding risk.
How does VKORC1 genotype affect warfarin sensitivity?
VKORC1 encodes vitamin K epoxide reductase, the enzyme that warfarin inhibits. The AA genotype of the -1639G>A promoter polymorphism leads to reduced VKORC1 expression, making the enzyme more easily inhibited by a given warfarin dose. AA patients are significantly more sensitive to warfarin and require lower doses, while GG patients are relatively resistant. VKORC1 genotype is considered the single strongest pharmacogenomic predictor of warfarin dose requirements.
Why does amiodarone increase warfarin effect?
Amiodarone is a potent inhibitor of CYP2C9 and CYP3A4, significantly reducing the clearance of S-warfarin. This interaction can increase warfarin's anticoagulant effect by 30–50% or more, dramatically elevating the risk of supratherapeutic INR and bleeding. Patients starting amiodarone while already on warfarin require empiric dose reduction (often 30–50%) and much more frequent INR monitoring during the transition period.
Should genetic testing always be done before starting warfarin?
Routine pharmacogenomic testing before warfarin initiation remains debated. Multiple randomized trials, including the COAG and EU-PACT trials, showed mixed results for clinical outcomes. Current guidelines from the American College of Chest Physicians do not mandate genetic testing but acknowledge its value in selected patients (e.g., those with unusual dose responses). When genetic data are unavailable, clinical algorithms using age, weight, and drug interactions alone still outperform fixed-dose empiric initiation.
Last updated: 2025-01-15 · Formula verified against primary sources.